1 / 38

What’s New with Hormonal Agents in Breast Cancer?

What’s New with Hormonal Agents in Breast Cancer?. Robin O’Brien BScPharm PharmD BCOP BC Cancer Agency Nov 2003. Goals. review hormonal therapy what’s new? which SERM for prevention? tamoxifen or an aromatase inhibitor for adjuvant therapy … or both? role of LHRH analogues?

dieter
Télécharger la présentation

What’s New with Hormonal Agents in Breast Cancer?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. What’s New with Hormonal Agents in Breast Cancer? Robin O’Brien BScPharm PharmD BCOP BC Cancer Agency Nov 2003

  2. Goals • review hormonal therapy • what’s new? • which SERM for prevention? • tamoxifen or an aromatase inhibitor for adjuvant therapy … or both? • role of LHRH analogues? • fulvestrant for palliative therapy?

  3. Good News: Decreased Mortalitywww.cancer.ca

  4. Bad News: Increased Incidencewww.cancer.ca

  5. Increased Incidence in Postmenopausal Women Only Incidence Mortality Age 70+ Age 50-69 Age 25-49 No Change

  6. Case 1 Brenda is bothered by troublesome hot flashes that wake her up at night. She is considering using estrogen replacement therapy but is worried about her risk of developing breast cancer. She also wonders about breast cancer prevention.

  7. Role of Hormones in Breast Cancer • estrogen declared a carcinogen (Dec. 2000) - endometrial and breast cancers • estrogen acts as fertilizer for breast cancer • tumour initiation and promotion • cancer risk related to lifetime estrogen exposure • estrogen & progesterone receptors found on tumours • combined estrogen + progesterone cancer risk • Women’s Health Initiative study terminated

  8. Estrogen Replacement Limit to short-term management of hot flashes. Continuous progestin appears safer than cyclic.

  9. Risk Factors age age at first menses age at first live birth mother or sister(s) with breast cancer previous biopsies atypical hyperplasia on biopsy NCI Risk Assessment Tool www.bcra.nci.nih.gov/brc/

  10. Primary Prevention: bcra.nci.nih.gov

  11. Prevention • avoid exogenous estrogens • have a large family early • breast feed • include soy products in diet • avoid alcohol • optimize weight

  12. SERMs for Primary Prevention Selective Estrogen Receptor Modulators • tamoxifen • anti-estrogenic in breast tissue • estrogenic in endometrium, may cause cancer • reduced ER(+) tumours by 49% in prevention trial • raloxifene - tamoxifen analogue, no effect on endometrium - reduced ER(+) tumours by 76% in MORE osteoporosis trial - not recommended for prevention outside of clinical trials - not recommended for women with a history of breast cancer

  13. Canadian Task Force on Preventive Health Care 5% risk warrants tamoxifen x 5 years Canadian Guidelines Can Med Assoc J 2001;164:1681

  14. Prevention Bottom Line • avoid exogenous estrogen • avoid alcohol, optimize weight • 5% 5-year risk warrants tamoxifen x 5 years

  15. Case 2 Susan has just completed adjuvant chemotherapy. Her physician recommends tamoxifen x 5 years but she has heard that aromatase inhibitors are “leading edge”. She wonders if she should be offered another option.

  16. Adjuvant Treatment surgery +/- radiation +/- chemotherapy ER(+) or PR(+) ER(-)PR(-) Tamoxifen x 5 years Tamoxifen contraindicated and postmenopausal no further treatment Low Risk High Risk no further treatment Letrozole x ? years Anastrozole x 5 years

  17. International Consensus Risk Assessment Minimal - Low RiskAvg. - High Risk Tumour Size £ 2cm > 2cm (+) ve (-) ve HR Status 1 2-3 Grade 35 years <35 years Age Lymph Node (-) ve (+) ve J Clin Oncol 2001;19:3817.

  18. 5-year Outcomes

  19. Adjuvant Hormones • not a cure, reduces recurrence risk if HR (+) • hot flashes most common side effect • tamoxifen x 5 years • gold standard for HR (+) tumours • may cause endometrial cancer, thromboembolism • aromatase inhibitors (anastrozole, letrozole) • anastrozole x 5 years instead of tamoxifen • letrozole x 5 years following tamoxifen • women must be postmenopausal • may cause arthritis, arthralgias, myalgias

  20. Estrogen Pathway Cholesterol Progesterone DHEA Aromatase Androstenedione Estrone Aromatase Testosterone Estradiol

  21. Sites of Aromatase Activity Clemens M, Goss P. NEJM 2001;344:276-85.

  22. NEJM 348:2432.

  23. ATAC: Anastrozole vs Tamoxifen as Adjuvant Therapy (early results) Objective Disease-free survival (DFS), safety A vs. T vs. A+T x 5 y adjuvant therapy for breast cancer in postmenopausal women. Method Multicentre, randomized, double-blind, n=9366. Interim analysis at median FU=33 months. Result DFS: anastrozole superior (except with chemo and radiation) Contralateral cancers: anastrozole superior - DFS, tolerability: anastrozole superior - Bone density: tamoxifen superior - Cognition: need longer follow-up - Overall survival difference: need longer follow-up Conclusion Lancet 2002;359:2131-9.

  24. ATAC Early Results % Event Free Months

  25. Number Needed to Treat NNT to prevent 1 additional recurrence over tamoxifen = 50 Incremental cost to prevent 1 additional recurrence over tamoxifen = $420,000

  26. Letrozole after Tamoxifen Adjuvant Therapy (early results) Objective Disease-free survival (DFS), contralateral cancers with letrozole 2.5 mg vs placebo x 5 years following tamoxifen adjuvant therapy in postmenopausal women. Method Multicentre, randomized, double-blind, n=5187. Interim analysis at median FU=29 months. Result DFS, contralateral cancers: letrozole superior Tolerability: hot flashes, arthritis, arthralgias, myalgias - DFS, contralateral cancers: letrozole superior - Bone density: need longer follow-up, use calcium and vit D - Overall survival difference: need longer follow-up - Optimal duration of therapy: unknown Conclusion NEJM 2003;349(19).

  27. Adjuvant Exemestane NSABP clinical trial testing exemestane after 5-years tamoxifen recently terminated following letrozole results.

  28. Adjuvant Bottom Line • tamoxifen remains the gold standard • anastrozole an option if tamoxifen contraindicated • letrozole after 5-years tamoxifen an option if high risk

  29. Case 3 Laura has metastatic breast cancer that responded to an aromatase inhibitor for almost a year but is now progressing. She is wondering about treatment options with other hormonal agents.

  30. Palliative Treatment Stage IV: Distant Metastases bisphosphonate if bone metastases Indolent Disease Aggressive Disease anthracycline? premenopausal postmenopausal HER2 (+) HER2 (-) LHRH analogue hormones trastuzumab + chemotherapy chemotherapy chemotherapy supportive care

  31. Palliative Hormones LHRH analogue if premenopausal adjuvant tamoxifen? none or > 1 year ago < 1 year ago Line 1, 2 3, 4, 5 6 or or tamoxifen anastrozole letrozole tamoxifen? fulvestrant? or exemestane megestrol testosterone

  32. Fulvestrantvia Special Access Programme • efficacy equivalent to anastrozole • 250 mg IM once monthly ($175 US) • studied in postmenopausal women • pure antiestrogen, no agonist activity • blocks and downregulates ER and PR • no known interactions, 3A4 substrate

  33. Bottom Line • adjuvant tamoxifen remains gold standard • adjuvant aromatase inhibitors an option for postmenopausal women • palliative LHRH analogues an option for premenopausal women • palliative fulvestrant available via SAP

  34. Avoid Hormonal NHPs

  35. Take Home Message • adjuvant tamoxifen remains the gold standard • aromatase inhibitors are an option for postmenopausal women • fulvestrant is available through SAP

More Related